NCT03466021 is a Phase 4 clinical trial of Liraglutide in Pulmonary Disease, Chronic Obstructive, sponsored by Claus Bogh Juhl.

Who is sponsoring NCT03466021?

NCT03466021 is sponsored by Claus Bogh Juhl.

What drugs are being tested in NCT03466021?

Interventions in NCT03466021: Liraglutide, Placebo.

What condition does NCT03466021 study?

NCT03466021 studies Pulmonary Disease, Chronic Obstructive.

Is NCT03466021 still recruiting?

NCT03466021 is currently completed. Last updated 16 March 2021.

Last reviewed 2021-03-16 · How we verify

NCT03466021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Liraglutide in Chronic Obstructive Pulmonary Disease

Completed Phase 4 Last updated 16 March 2021

What this trial tests

Phase 4 trial testing Liraglutide in Pulmonary Disease, Chronic Obstructive in 40 participants. Completed in 31 May 2020.

Timeline

1 January 2018

Primary endpoint
31 May 2020

31 May 2020

Quick facts

Lead sponsor	Claus Bogh Juhl
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	1 January 2018
Primary completion	31 May 2020
Estimated completion	31 May 2020
Sites	2 locations across Denmark

Drugs / interventions tested

Liraglutide (liraglutide) — full drug profile →
Placebo

Conditions studied

Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →

Sponsor

Claus Bogh Juhl

Who can join

Adults 30 to 75, any sex, with Pulmonary Disease, Chronic Obstructive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a 44 weeks, prospective, randomized, placebo-controlled, double-blinded, parallel group two-center trial. Forty patients are recruited among the outpatients of the chronic obstructive pulmonary disease (COPD) clinic, Hospital of South West Jutland and Lillebælt Hospital according to the inclusion and exclusion criteria. The patients are randomized to receive liraglutide 3 mg per day (initial dose 0.6 mg, increasing by 0.6 mg weekly until 3 mg is reached) or placebo. At baseline, after four weeks (assessment of the acute effect of liraglutide), 20 weeks, and 40 weeks (assessment of the combined effect of liraglutide and weight loss) and at week 44 (assessment of the weight-loss after discontinuation of liraglutide) the patients are assessed by physical examination, carbon monoxide (CO) diffusion test, pulmonary function test, biomarkers of inflammation (CRP, interleucine-6 (IL-6), monocyte chemitactic protein-1 (MCP-1)), Fluorodeoxyglucose (FDG)/PET-CT scan of the lungs, 6-minute walking test, respiratory polygraphy and validated questionnaires including basic dyspnea index, transition dyspnea index, COPD Assessment Test (CAT)-score, short-form-36 (SF-36) and Epworth Sleepiness Score.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease.
Altintas Dogan AD, Hilberg O, Hess S, Jensen TT, et al · · 2022 · cited 36× · PMID 35237033 · DOI 10.2147/copd.s350133
Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis.
Yeh TL, Tsai MC, Tsai WH, Tu YK, et al · · 2023 · cited 33× · PMID 36696429 · DOI 10.1371/journal.pone.0278685
Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis.
Yang R, Zhang L, Guo J, Wang N, et al · · 2025 · cited 12× · PMID 40181368 · DOI 10.1186/s12967-025-06302-y
Effects of Treatment with Liraglutide on Health-Related Quality of Life and Obstructive Sleep Apnea in People with Obesity and Chronic Obstructive Pulmonary Disease
Dogan ADA, Hess S, Jensen TT, Bladbjerg E, et al · · 2022 · cited 1× · DOI 10.21203/rs.3.rs-1665063/v1
Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.
Wolsing SK, Dogan ADA, Juhl CB, Hess S, et al · · 2026 · PMID 41871584 · DOI 10.1111/cob.70079
GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes.
Georgakopoulou VE, Dalamaga M. · · 2026 · PMID 41717504 · DOI 10.1016/j.metop.2026.100449
FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.
Dogan ADA, Christensen TQ, Jensen TT, Juhl CB, et al · · 2024 · PMID 38902794 · DOI 10.1186/s13104-024-06820-w

Verify or expand the search:

Other trials of Liraglutide

Trials testing the same drug.

NCT07225816 — Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in · Phase 1 · recruiting
NCT06818292 — Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists · NA · completed
NCT06283641 — Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. · completed
NCT06501326 — Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease · Phase 4 · unknown
NCT05756764 — Anti-obesity Pharmacotherapy and Inflammation · active not recruiting

Other recruiting trials for Pulmonary Disease, Chronic Obstructive

Currently open trials in the same condition.

NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting

Other Claus Bogh Juhl trials

Trials by the same sponsor.

NCT05176132 — South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03466021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Claus Bogh Juhl
Last refreshed: 16 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03466021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing